Sanofi Winthrop Industrie has withdrawn its application to the European Medicines Agency (EMA) for Dupixent's use in treating moderate-to-severe bullous pemphigoid in adults. This withdrawal indicates a setback for the drug's expansion into this specific indication within the EU market, potentially impacting future revenue projections for this particular use case.
Sanofi Winthrop Industrie has formally withdrawn its application to the EMA for Dupixent (dupilumab) to treat moderate-to-severe bullous pemphigoid in adults. This means the drug will not be approved for this specific indication in the European Union, at least for now. While Dupixent is a blockbuster drug with numerous approved indications, this withdrawal represents a minor setback for Sanofi's efforts to expand its market reach. The short-term implication is a slight dampening of potential future revenue from this specific use case, but it's unlikely to significantly impact Sanofi's overall financial performance given Dupixent's broad success. Traders should note this as a minor negative for SNY, indicating a slight reduction in the drug's total addressable market within the EU.